GABANEVRAL caps. 300 mg. 100 caps

Tax included

Gabanevral a structure analogous to gamaaminomaslenata acid, but the mechanism of action is different from that of many other drugs that interact with its synapses. Possesses anticonvulsant action


GABANEVRAL caps. 300 mg. 100 caps

 GABANEVRAL caps. 300 mg, Monotherapy for adults and children over 12 years with partial onset seizures with or without secondary generalization


Gabanevral a structure analogous to gamaaminomaslenata acid, but the mechanism of action is different from that of many other drugs that interact with its synapses. Has anticonvulsant activity.

Gabanevral is used to treat:




 Monotherapy in adults and children over 12 years with partial onset seizures with or without secondary generalization;

 Adjunctive therapy in adults and children over 3 years with partial seizures with or without secondary generalization.


Neuropathic pain


 Treatment of neuropathic pain in patients over 18 years.




Gabanevral not be used in patients with hypersensitivity to the active substance or to any of the excipients.

In this medicinal product, please note the following:

Treatment with the product is not established phenomenon of increased symptoms after stopping treatment. However, treatment discontinuation should be gradual due to risk of unlock status epilepticus. The same goes for dose reduction, discontinuation or replacement with another anticonvulsant. This should be done gradually over a period of one week. This product is not effective in absence seizures.

Patients taking Gabanevral may show changes in mood and behavior.

The product is used with caution in patients with a history of mental illness because of the risk of psychotic episodes. They resolved with dose reduction or discontinuation.

Small number of people, epileptics such as gabanevral have had thoughts of harming or killing yourself. If you have these, contact your doctor.

Application Gabanevral and intake of food and beverages

No evidence of a need for a special diet or restriction of certain foods and drinks during treatment with this product.




Before taking any medicines, check with your doctor or pharmacist

There are no adequate studies in pregnant women. It is therefore recommended Gabanevral be used in those cases when the potential benefit to the mother is greater than the potential risk to the fetus.




Before taking any medicines, check with your doctor or pharmacist

Gabanevral passes into breast milk. Therefore, you should carefully consider whether the benefits of treatment clearly outweigh the risks of it.


Driving and operating machinery


Patients should be advised not to drive or engage in activities requiring a high degree of concentration until you are sure that the product does not change their reactivity.


Taking other medicines


Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, even if they have not been prescribed by a doctor

No evidence of interactions between Gabanevral and phenytoin, phenobarbital, valproic acid and karabamazepin.

Combined use of the product with an oral contraceptive containing norethindrone and / or ethinyl estradiol, does not affect the pharmacokinetics.

The bioavailability of the product decreased by about 20% when administered with antacids containing aluminum and magnesium. It is desirable that the product should be administered at least 2 hours after taking antacids.

Probenecid does not affect renal excretion of Gabanevral.

In determining the protein in urine tests Ames N-Multitrix SG can be observed false positive results. Preferably in this case is to use a more specific test with sulfosalicylic acid.

In patients receiving concomitant morphine Gabanevral may increase the concentration of product in the plasma. These patients should be monitored for signs of CNS depression such languor and doses of morphine Gabanevral must be reduced.




Always Gabanevral as your doctor!


 Adults and children over 12 years - starting dose of 300 mg three times daily on day 1, as described in the table. The daily dose divided into three equal intake can be increased to a maximum dose of 3600 mg. The maximum time between doses in the triple regimen should not exceed 12 hours to prevent seizures.


 For children 3 to 12 years - the effective dose of the product is 25-35 mg / kg / day, taken in three equal assumed as shown in Table 2. Originally titration to achieve therapeutically effective dose is made in the first three days by applying 10 mg / kg / day on day 1, 20 mg / kg / day on day 2 and 30 mg / kg / day for 3 days as shown in Table 3. The daily dose in three divided doses may be increased to a maximum dose of 35 mg / kg / day.


If required discontinuation of the product and / or the addition of another anticonvulsant to therapy, this should be done gradually over a minimum of one week.

Neuropathic pain in adults

The starting dose is 900 mg / day, taken in three equal doses. This dose can be increased as necessary until the clinical response to a maximum dose of 3600 mg / day.

Patients with renal insufficiency


The total daily dose should be administered in three doses.

 To be taken as 300 mg every other day.

In patients undergoing hemodialysis is recommended loading dose of 300 to 400 mg after each 4 hours of hemodialysis take 200 to 300 mg Gabanevral.

If you have the impression that the effect of Gabanevral is too strong or too weak, talk to your doctor or pharmacist!

If you take too much of the drug:

When taking a higher dose than prescribed immediately seek help from a doctor!

Acute life-threatening toxicity in overdose Gabanevral at doses up to 49 g have not been established. Symptoms of overdose include dizziness, double vision, slurred speech, drowsiness, lethargy and diarrhea. Since the product is absorbed to a lesser extent in high doses, it limits the absorption and overdose.

The product can be removed from the body by hemodialysis, but this is not recommended. In patients with severe renal impairment is the treatment of choice.

If you forget to Gabanevral:

If you forget to take the next dose, take the missed as soon as possible, but do not take both to the next.




Like all medicines, Gabanevral can cause side effects


Epilepsy in adults


Since Gabanevral was used more frequently in combination with other antiepileptic drugs, it is not possible to determine which product caused the corresponding reaction.

 The most common adverse reactions (> 1/10) - languor and confusion;

 Common possible side effects (between 1/10 and 1/100) - ataxia, fatigue, visual problems (nystagmus), tremor, double 6

vision, myopia, impaired speech, forgetfulness, weight loss, numbness, joint pain, purpura, heartburn, anxiety, weight gain, urinary infections and pharyngitis

Uncommon possible side effects (between 1/100 and 1/1000) - reduced number of white blood cells, nervousness, fever, impotence.

Rarely loss of urine, inflammation of the pancreas, liver enzymes, severe skin reactions (erythema multiforme syndrome Stevens Johnson), depression, emotional lability, hostility, changes in thinking and psychoses / hallucinations.

Been reported instability of glucose in patients with diabetes. More rarely reported muscle pain, headache, nausea and / or vomiting.


Epilepsy in children


In children aged 3-12 years the most common (> 10%) adverse reactions were emotional lability, nervousness, changes in thinking (abnormal thoughts). All these events were rated as mild to moderate and do not require frequent discontinuation.

In children aged 3-12 years in clinical trials, adverse reactions with an incidence of 2% or more compared with placebo: languor, fatigue, weight gain, hostility, emotional lability, confusion, movement disorders (hyperkinesia), nausea / vomiting, viral infection, fever, bronchitis, respiratory infections. Some of these effects can be attributed to the banal viral disease in children.

Neuropathic pain

The most common adverse reactions (> 1/10) associated with neuropathic pain are the product confusion and languor. Common side effects (between 1/10 and 1/100) - diarrhea, dry mouth, peripheral edema, weight gain, abnormal gait, forgetfulness, movement disorder (ataksiya), abnormal thinking, rash and short-sightedness. Uncommon side effects (between 1/100 and 1/1000) - injuries, weight loss, back pain, constipation, flatulence, nausea, disorientation, hyperesthesia, dizziness, dyspnea, pharyngitis.

Adverse reactions in postmarketing surveillance.


Other adverse reactions observed in the treatment of epilepsy and neuropathic pain is acute renal failure, allergic reactions, incl. urticaria, alopecia, chest pain, hepatitis, jaundice, hallucinations, movement disorders (choreoathetosis, dyskinesia and dystonia), palpitations, low platelets, tinnitus.


Of adverse events following discontinuation of treatment most frequently reported anxiety, insomnia, nausea, pain and sweating.

If you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.




At temperatures below 25 ° C.

Keep out of reach of children!

Do not use after the expiry date stated on the package!

New product